Oral valganciclovir prophylaxis in kidney transplant recipients

Détails

ID Serval
serval:BIB_0A3A5D924FE1
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Oral valganciclovir prophylaxis in kidney transplant recipients
Titre de la conférence
12th International Society for infectious Diseases
Auteur(s)
Manuel O., Fellay J., Venetz J.P., Sturzenegger N., Meylan R., Pascual M.
Adresse
Lisbon, Portugal, June 15-18, 2006
ISBN
1201-9712
Statut éditorial
Publié
Date de publication
2006
Peer-reviewed
Oui
Volume
10
Série
International Journal of Infectious Diseases
Pages
S16
Langue
anglais
Notes
Publication type : Meeting Abstract
Résumé
Background: Immunosuppressive and antivira[ prophy[
actic drugs are needed to prevent acute rejection
and infection after organ transplantation.
We assessed the effectiveness of a new combined
regimen introduced at our transplantation center.
Methods: We reviewed at[ consecutive patients
who underwent kidney transplantation at our institution
over a 5.5-year period, with a follow-up
of at [east 6 months. Patients transplanted from
1/2000 to 3/2003 (Period 1) were compared to
patients transplanted from 4/2003 to 7/2005 (Period
2). In period 1, patients were treated with
Basi[iximab, Cic[osporin, steroids and Mycophenotate
or Azathioprine. Prophylaxis with Va[acic[
ovir was prescribed in CMV D+/R- patients; otherwise,
a preemptive antivira[ approach was used.
In period 2, immunosuppressive drugs were Basi[-
iximab, Tacro[imus, steroids and Mycopheno[ate.
A 3-month CMV prophylaxis with Va[gancic[ovir was
used, except in D-/R- patients.
Results: Sixty-three patients were transplanted in
period 1 and 70 patients in period 2. Baseline
characteristics of both groups were comparable;
in particular 17% of patients were CMV D+/R- in
period 1 compared to 23% in period 2 (p=0.67).
Acute rejection was more frequent in period 1
than in period 2 (40% of patients vs 7%, respectively
p<0.001). Nineteen patients (30%) in period
1 were diagnosed with CMV infection/disease
that required treatment, compared with 8 patients
(11.4%) in period 2 (p = 0.003). Of these 8 patients,
at[ had CMV infection/disease after discontinuation
of Va[gancic[ovir prophylaxis, 6 were D+/R- (75%),
and at[ were treated with oral Va[gancic[ovir. There
was no difference between periods in terms of
incidence of BK nephropathy, post-transplant [ymphopro[
iferative disease, graft toss, and mortality.
Conclusions: These results indicate that a 3-month
course of oral Va[gancic[ovir is very effective to
prevent CMV infection/disease in kidney transplantation.
Late-onset CMV disease is a residual problem
in D+/R- patients receiving VGC prophylaxis.
Mots-clé
,
Web of science
Création de la notice
05/01/2011 11:55
Dernière modification de la notice
20/08/2019 13:32
Données d'usage